Your browser doesn't support javascript.
Coexistence of growth hormone, adrenocorticotropic hormone, and testosterone deficiency associated with coronavirus disease 2019: a case followed up for 15 months.
Yoshimura, Kai; Yamamoto, Masaaki; Inoue, Tomoya; Fukuoka, Hidenori; Iida, Keiji; Ogawa, Wataru.
  • Yoshimura K; Division of Diabetes and Endocrinology, Hyogo Prefectural Kakogawa Medical Center, Kakogawa 675-8555, Japan.
  • Yamamoto M; Division of Diabetes and Endocrinology, Kobe University Hospital, Kobe 650-0017, Japan.
  • Inoue T; Division of Diabetes and Endocrinology, Kobe University Hospital, Kobe 650-0017, Japan.
  • Fukuoka H; Division of Diabetes and Endocrinology, Kobe University Hospital, Kobe 650-0017, Japan.
  • Iida K; Division of Diabetes and Endocrinology, Hyogo Prefectural Kakogawa Medical Center, Kakogawa 675-8555, Japan.
  • Ogawa W; Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.
Endocr J ; 69(11): 1335-1342, 2022 Nov 28.
Article in English | MEDLINE | ID: covidwho-2140769
ABSTRACT
Coronavirus disease 2019 (COVID-19) is associated with endocrine disorders, but their long-term clinical course remains unclear. We here report the 15-month clinical course for an individual with multiple endocrine disorders of the pituitary gland and testis likely triggered by COVID-19. A 65-year-old man with no history of endocrinopathy was admitted for acute COVID-19 pneumonia. Although his respiratory condition improved after administration of antiviral drugs, his blood pressure dropped suddenly to a preshock level and was refractory to vasopressors. The circulating adrenocorticotropic hormone (ACTH) and cortisol concentrations were low, and secondary adrenal insufficiency was suspected. Administration of hydrocortisone rapidly ameliorated the hypotension, and the patient was discharged taking 15 mg of hydrocortisone daily. An insulin tolerance test performed 3 months later revealed impaired ACTH, cortisol, and growth hormone (GH) responses, indicative of combined hypopituitarism. The patient also manifested symptoms of hypogonadism, and a hormonal workup suggested primary hypogonadism. At 12 months after discharge, GH and ACTH responses had recovered completely and partially, respectively. After another 3 months, basal ACTH and cortisol levels had been restored to the normal range and the patient discontinued hydrocortisone replacement without exacerbation of symptoms, although his hypogonadism persisted. The patient thus developed transient GH and ACTH deficiency that lasted for more than a year as well as persistent primary hypogonadism during intensive care for COVID-19. Certain prolonged symptoms of COVID-19 might be accounted for by such hormonal disturbance.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Human Growth Hormone / COVID-19 / COVID-19 Drug Treatment / Hypogonadism Type of study: Case report / Prognostic study Topics: Long Covid Limits: Aged / Humans / Male Language: English Journal: Endocr J Journal subject: Endocrinology Year: 2022 Document Type: Article Affiliation country: Endocrj.EJ22-0108

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Human Growth Hormone / COVID-19 / COVID-19 Drug Treatment / Hypogonadism Type of study: Case report / Prognostic study Topics: Long Covid Limits: Aged / Humans / Male Language: English Journal: Endocr J Journal subject: Endocrinology Year: 2022 Document Type: Article Affiliation country: Endocrj.EJ22-0108